The first of a two-part series on gene therapy. Gene therapy has transformed the treatment landscape for hemophilia, though its path has not always been straightforward. In this webinar, we’ll review the promise of gene therapy, the expectations that surrounded its development, and its current status in the United States and Europe. We’ll discuss the importance of shared decision-making when considering gene therapy,  and look ahead to what future innovations may bring. There will be ample time for questions during the live Q&A.

Speakers:

Nathan T. Connell, MD, MPH, FACP

Dr. Nathan T. Connell is Associate Professor of Medicine at Harvard Medical School, Associate Director of the Boston Bleeding Disorders Center, and Vice Chair of Medicine at Mass General Brigham. He is an academic hematologist with expertise in inherited bleeding disorders, von Willebrand disease, hemostatic and antithrombotic stewardship, and systems-based hematology. His scholarship and leadership focus on translating subspecialty expertise into scalable models of care across health systems.

Brian O'Mahony

Brian O’Mahony is the Chief Executive of the Irish Haemophilia Society,  President of the European Haemophilia Consortium and former President of the World Federation of Hemophilia. He is a Fellow of the Institute of Biomedical Sciences (UK) and a Fellow of the Academy of Clinical Science and Laboratory Medicine (Ireland) and an assistant adjunct Professor in Health Service Management in Trinity College, Dublin. Brian O’Mahony has severe hemophilia B.